Revolution Medicines announced that Rasonque™ (daraxonrasib), a groundbreaking new targeted therapy for adults with advanced pancreatic cancer, was FDA-approved on August 26, 2026. This once-daily pill marks one of the most significant medical breakthroughs for pancreatic cancer treatment in decades across the United States and global oncology communities.
If you or a loved one is navigating a metastatic pancreatic cancer diagnosis, here is a breakdown of how Rasonque works, who can take it, its clinical trial results, and what side effects to expect.
What Is Rasonque™ and How Does It Work?
For decades, patients diagnosed with advanced pancreatic adenocarcinoma relied almost entirely on traditional intravenous (IV) chemotherapy. While chemotherapy works by targeting all fast-growing cells throughout the body, Rasonque is a targeted therapy, specifically a first-in-class RAS inhibitor.
Targeting the "RAS" Switch
In more than 90% of pancreatic cancers, the disease is driven by a specific protein inside cells called RAS (most notably KRAS mutations like G12D, G12V, and G12R).
In healthy cells, the RAS protein acts like a light switch, turning cell growth on and off as needed.
In pancreatic cancer, this switch becomes stuck in the "ON" position, signaling cancer cells to multiply rapidly and spread.
For years, scientists referred to the RAS protein as "undruggable" because its smooth shape made it hard for medicines to stick to it. Rasonque acts like a molecular glue, blocking the active RAS protein directly to stop the growth signals fueling the tumor.
Who Is Eligible for Rasonque?
The U.S. FDA approved Rasonque for adult patients with metastatic pancreatic adenocarcinoma (cancer that has spread beyond the pancreas to other organs) who meet either of the following criteria:
They have already received at least one prior systemic therapy (such as standard IV chemotherapy), OR
They are not candidates for multi-agent combination chemotherapy due to health or tolerance concerns.
Doctors can prescribe Rasonque regardless of whether a specific RAS tumor mutation is identified on a genetic test, making it widely accessible for patients across major U.S. cancer centers.
How Well Does Rasonque Work? (Clinical Trial Results)
The FDA's decision was supported by data from RASolute 302, a global Phase 3 clinical trial involving 500 patients. Led by researchers at leading U.S. institutions like the Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center, the study compared Rasonque directly against standard chemotherapy regimens.
The results showed clear, statistically significant benefits:
Nearly Doubled Overall Survival: Patients taking Rasonque achieved a median overall survival rate of 13.2 months, compared to 6.7 months for patients receiving standard chemotherapy.
Reduced Risk of Death: Rasonque reduced the risk of death by 60% compared to chemotherapy.
Slower Disease Progression: Median progression-free survival reached 7.2 months on Rasonque, compared to 3.6 months on chemotherapy.
Better Pain and Quality of Life Control: Patients reported a significant delay in pain worsening, allowing them to maintain their overall quality of life for twice as long as those on traditional chemotherapy.
How Is Rasonque Taken?
Rasonque is an oral pill (300 mg) taken once daily by mouth at home.
Because it is taken orally, patients avoid spending long hours attached to intravenous lines in infusion clinics. Oncologists note that this convenience significantly reduces the day-to-day burden of cancer care.
Common Side Effects
While Rasonque generally offers more manageable side effects compared to traditional chemotherapy, it can still cause side effects that require monitoring by your healthcare team.
Most Frequent Side Effects Include:
Skin Reactions: Rashes, dry skin, or itching (the most common reaction).
Digestive Symptoms: Diarrhea, mouth sores (stomatitis), nausea, vomiting, or abdominal pain.
General Symptoms: Decreased appetite, fatigue, and swelling (edema) in the hands or feet.
Your oncology care team can prescribe targeted creams or oral medications to help manage skin and digestive symptoms as soon as they appear.
Next Steps for Patients and Caregivers
Speak with Your Oncologist: Ask your cancer care team whether Rasonque (daraxonrasib) is an appropriate treatment option for your specific stage and medical history.
Explore Patient Financial Assistance: Rasonque is supported by a comprehensive patient program called (ON)Path™, which assists U.S. patients with health insurance navigation, copay cards, and financial assistance options. Organizations like the Pancreatic Cancer Action Network (PanCAN) also offer free navigation services for families seeking care options.
